"schizophrenia uptodate" - Google News
[unable to retrieve full-text content]
Open Label Phase 3 Study of Brilaroxazine for Schizophrenia Shows Efficacy, Tolerability Psychiatric Times"mdd single episode moderate" - Google News
[unable to retrieve full-text content] Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study Nature.com
Comments
Post a Comment